As­traZeneca's non-prof­it vac­cine is, for now, cost­ing them mon­ey

For the first earn­ings re­port of the year, As­traZeneca in­vent­ed a new met­ric: the prof­it they’d have if you didn’t count their Covid-19 vac­cine costs.

When As­traZeneca an­nounced last year that they would de­vel­op Ox­ford’s Covid-19 can­di­date, they said they would sell it on a not-for-prof­it ba­sis dur­ing the pan­dem­ic. The terms ful­filled the vac­cine’s aca­d­e­m­ic in­ven­tors’ de­sire to see their shot de­ployed cheap­ly around the world, while al­so al­low­ing the drug­mak­er to do some good and, po­ten­tial­ly, se­cure a mas­sive PR coup.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN